Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Zyprexa ® (olanzapine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Zyprexa® (olanzapine): Feeding tube
Administration of Zyprexa coated tablets or Zyprexa Velotab through a feeding tube is not part of the approved methods of administration. Lilly has no data to support the administration of Zyprexa through a gastric tube.
cFAQ
cFAQ
UK_cFAQ_OLZ045_Y1_FEEDING_TUBE
en-GB
Handling and Safety Concerns
Exposure to tablet powder (either airborne or by dermal contact) generated during the breaking or crushing of olanzapine tablets has the potential risks for contact dermatitis following repeated exposure.1
Symptoms have included rash with redness, swelling, and scaling of the affected skin areas. Positive reactions have been verified by patch testing with olanzapine (0.1%). Based on the clinical dose, olanzapine is highly potent.1
Likewise, olanzapine may be irritating to the eyes based on animal studies. Attention and care should be exercised not to inadvertently transfer material from the hands to the eye.2
Additional safety information about olanzapine can be found in the full prescribing information and the Material and Safety Data Sheet, available upon request from Eli Lilly and Company.
References
1Olanzapine [material safety data sheet]. Indianapolis, IN: Eli Lilly and Company; 2019.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 08 January 2021
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays